Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 Bispecific CAR-T for Relapsed/Refractory B-Cell Hematological Tumors
NCT06735495Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD22 bispecific CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma. Started Nov 2024; status: recruiting.
02
Drugs
CD22 bispecific CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT06735495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735495.